30355-61-4

Basic information

• Product Name: 6-(CHLOROMETHYL)-N-(4-CHLOROPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE
• Synonyms: 1,3,5-Triazine-2,4-diamine,6-(chloromethyl)-N-(4-chlorophenyl)- (9CI); s-Triazine, 2-amino-4-(p-chloroanilino)-6-(chloromethyl)-(6CI,8CI)
• CAS NO: 30355-61-4
• Molecular Formula: C₁₀H₉Cl₂N₅
• Molecular Weight: 270.12
• Mol File: 30355-61-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 180 °C (decomp)(Solv: water (7732-18-5); methanol (67-56-1))
• Boiling Point: 501.4°Cat760mmHg
• Flash Point: 257°C
• Appearance: /
• Density: 1.525g/cm³
• Vapor Pressure: 3.49E-10mmHg at 25°C
• Refractive Index: 1.704
• PKA: 3.56±0.10(Predicted)
• CAS DataBase Reference: 6-(CHLOROMETHYL)-N-(4-CHLOROPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(CHLOROMETHYL)-N-(4-CHLOROPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE(30355-61-4)
• EPA Substance Registry System: 6-(CHLOROMETHYL)-N-(4-CHLOROPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE(30355-61-4)

Safety Data

• Hazardous Substances Data: 30355-61-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H9Cl2N5/c11-5-8-15-9(13)17-10(16-8)14-7-3-1-6(12)2-4-7/h1-4H,5H2,(H3,13,14,15,16,17)

Upstream product

• 4022-81-5 1-(4-chlorophenyl)biguanide hydrochloride 
• 96-34-4 methyl chloroacetate 
• 106-47-8 4-chloro-aniline 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 1269527-14-1 6-[(1H-benzo[d]imidazol-2-ylthio)methyl]-N₂-(4-chlorophenyl)-1,3,5-triazine-2,4-diamine 
• 1269527-19-6 N₂-(4-chlorophenyl)-6-((5-methyl-1H-benzo[d]imidazol-2-ylthio)methyl)-1,3,5-triazine-2,4-diamine 

Relevant articles and documents

Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2

By screening a focused library of kinase inhibitor analogues in a phenotypic co-culture assay for angiogenesis inhibition, we identified an aminotriazine that acts as a cytostatic nanomolar inhibitor. However, this aminotriazine was found to be completely inactive in a whole-kinome profiling assay. To decipher its mechanism of action, we used the online target prediction tool PPB2 (http://ppb2.gdb.tools), which suggested lysophosphatidic acid acyltransferase β (LPAAT-β) as a possible target for this aminotriazine as well as several analogues identified by structure–activity relationship profiling. LPAAT-β inhibition (IC50 ≈15 nm) was confirmed in a biochemical assay and by its effects on cell proliferation in comparison with a known LPAAT-β inhibitor. These experiments illustrate the value of target-prediction tools to guide target identification for phenotypic screening hits and significantly expand the rather limited pharmacology of LPAAT-β inhibitors.

Synthesis and in vitro evaluation of 2,4-diamino-1,3,5-triazine derivatives as neuronal voltage-gated sodium channel blockers

Neuronal sodium channels blockers interfere with ion flux and have been used for managing neuropathic pain, epilepsy, and cerebral ischemic disorders. In the current study, four groups of 2,4-diamino-1,3,5-triazine derivatives were synthesized and investigated for their neuronal sodium channels binding activity. 5-Aryl-1,3,5-triazaspiro[5.5]undeca-1,3-diene-2,4-diamines (4a-4j) were found to have the best neuronal sodium binding activity among the four groups of triazines evaluated. Derivatives 4a-4j blocked the sodium channels with IC50 values ranged from 4.0 to 14.7 μM. The result from this study showed that analogues of 2,4-diamino-1,3,5-triazines could be used as leads for the discovery of neuronal sodium channels blockers for managing central nervous system related disorders.